DOI:
10.1055/s-00034925
Hämostaseologie
LinksClose Window
References
Gibson CM, Mega JL, Burton P. et al.
Rationale and design of the anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome.
Am Heart J 2011;
161 (05) 815-821.e6
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.